Cargando…
New Strategies in Controlling Drug Resistance
BACKGROUND: Chronic myeloid leukemia (CML) is most often caused by the translocation of chromosomes 9 and 22 to create the fusion protein, BCR-ABL. This constitutively active tyrosine kinase promotes cell division and blocks apoptosis, leading to unregulated growth of hematopoietic stem cells. Imati...
Autor principal: | Frame, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437929/ https://www.ncbi.nlm.nih.gov/pubmed/17970610 http://dx.doi.org/10.18553/jmcp.2007.13.s8-a.13 |
Ejemplares similares
-
Introduction: Optimizing Outcomes Through Pharmaceutical Advances in the Treatment of Chronic Myeloid Leukemia
por: Frame, David
Publicado: (2007) -
Pharmacy Management Strategies for Improving Drug Adherence
por: Fleming, William K.
Publicado: (2008) -
Can CER Be an Effective Tool for Change in the Development and Assessment of New Drugs and Technologies?
por: Brixner, Diana I., et al.
Publicado: (2012) -
Clinical Case Study: Achieving Long-term Control of Insulin Resistance
por: Cornell, Susan A.
Publicado: (2007) -
Strategies for Optimizing Treatment Outcomes
por: Jones Freeman, Elyce L.
Publicado: (2003)